Exclusive: Backed by former Google CEO’s VC, a Colorado biotech hatches platform to evolve degraders
It was 2012, and Doug Chapnick was fed up with traditional biochemistry research.
That kind of thinking first led him to a Department of Defense-funded project, which involved white powders and Rube Goldberg-esque experiments, and then to founding a biotech company called BioLoomics, which is trying to develop new protein degraders via directed evolution, or lab-based natural selection, in human cell experiments.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.